Deb Shoumitro, Nancarrow Tom, Limbu Bharati, Sheehan Rory, Wilcock Mike, Branford David, Courtenay Ken, Perera Bhathika, Shankar Rohit
Faculty of Medicine, Department of Brain Sciences, Imperial College London, UK.
University of Exeter Medical School, UK.
BJPsych Open. 2020 Sep 17;6(5):e112. doi: 10.1192/bjo.2020.97.
A high proportion of adults with intellectual disabilities are prescribed off-licence antipsychotics in the absence of a psychiatric illness. The National Health Service in England launched an initiative in 2016, 'Stopping over-medication of people with a learning disability [intellectual disability], autism or both' (STOMP), to address this major public health concern.
To gain understanding from UK psychiatrists working with adults with intellectual disabilities on the successes and challenges of withdrawing antipsychotics for challenging behaviours.
An online questionnaire was sent to all UK psychiatrists working in the field of intellectual disability (estimated 225).
Half of the 88 respondents stated that they started withdrawing antipsychotics over 5 years ago and 52.3% stated that they are less likely to initiate an antipsychotic since the launch of STOMP. However, since then, 46.6% are prescribing other classes of psychotropic medication instead of antipsychotics for challenging behaviours, most frequently the antidepressants. Complete antipsychotic discontinuation in over 50% of patients treated with antipsychotics was achieved by only 4.5% of respondents (n = 4); 11.4% reported deterioration in challenging behaviours in over 50% of patients on withdrawal and the same proportion (11.4%) reported no deterioration. Only 32% of respondents made the diagnosis of psychiatric illness in all their patients themselves. Family and paid carers' concern, lack of multi-agency and multidisciplinary input and unavailability of non-medical psychosocial intervention are key reported factors hampering the withdrawal attempt.
There is an urgent need to develop national guidelines to provide a framework for systematic psychotropic drug reviews and withdrawal where possible.
很大一部分智障成年人在没有精神疾病的情况下被开具了非处方药的抗精神病药物。英国国民医疗服务体系于2016年发起了一项倡议,即“停止对有学习障碍(智障)、自闭症或两者皆有的人群过度用药”(STOMP),以解决这一重大公共卫生问题。
了解在英国与智障成年人一起工作的精神科医生在停用抗精神病药物以应对具有挑战性的行为方面所取得的成功和面临的挑战。
向所有在智障领域工作的英国精神科医生(估计有225人)发送了一份在线问卷。
88名受访者中有一半表示他们在5年多以前就开始停用抗精神病药物,52.3%的受访者表示自STOMP倡议发起以来,他们开始使用抗精神病药物的可能性降低。然而,从那时起,46.6%的人针对具有挑战性的行为开具其他类别的精神药物而非抗精神病药物,最常用的是抗抑郁药。只有4.5%的受访者(n = 4)在超过50%接受抗精神病药物治疗的患者中实现了完全停用抗精神病药物;11.4%的受访者报告称,超过50%的患者在停药时具有挑战性的行为恶化,同样比例(11.4%)的受访者报告称没有恶化。只有32%的受访者亲自对所有患者进行精神疾病诊断。家庭和付费护理人员的担忧、缺乏多机构和多学科投入以及无法获得非医学心理社会干预是报告的阻碍停药尝试的关键因素。
迫切需要制定国家指南,为系统的精神药物审查和尽可能的停药提供框架。